This round will allow Zerigo Health to respond to the increasing demand for its innovative connected chronic skin condition solution for the over 40 million Americans living with psoriasis, vitiligo, and eczema.
The round is led by a new investment of $90 million from Mérieux Equity Partners and $60 million from Vitruvian Partners, an existing financial investor, demonstrating confidence in the company’s ambitious plans.
The XGAL3® therapeutic apheresis device is the early-mover for the treatment of AKI. ETI has demonstrated significant survival benefits in preclinical models and their prototype device has successfully removed GAL-3 from human blood plasma.
Fidmi Medical CEO Shahar Millis remarked, "We are truly excited to embark on the market entry phase for Fidmi. With FDA clearance and strategic collaboration with Micro-Tech, a leader in this field, we are well-positioned to make a real difference for people requiring long-term nutritional support."
Recently, it completed its Series B fundraising led by Legend Capital, followed by CD Capital, SAIF Partners, Chengwei Chuangban and Co-win Ventures. Existing investors Lilly Asia Ventures and Kaitai Capital also participated in the funding round.
"We decided to invest in Bisu because we believe its home health lab technology, which provides affordable access to actionable health data, is very innovative and has huge potential," says Hiroaki Kageyama, President of ASICS Ventures.
The Series C funding round includes ICONIQ Growth, Sequoia Capital India, Perceptive Advisors, Corner Ventures, LTS Investments, Helena and Sofina, enabling Twin Health to scale its Whole Body Digital Twin™ service and help solve the chronic metabolic disease health crisis.